Close
18/03/2014
The public-private partnership ESTEVE-UAB is bearing fruit
ESTEVE has announced the signing of two agreements that will enable it to progress the development of its gene therapeutic for the treatment of Sanfilippo A Syndrome and begin a phase I/II clinical trial in 2015. The agreements are with the North American biotechnology company REGENX Biosciences, LLC (REGENX) and with the French non for profit organization GÉNÉTHON.
 
Sanfilippo A is a rare and devastating neurodegenerative disease that affects approximately 1 in every 100.000 children that rarely survive past adolescence.

This gene therapy program is being developed in a public-private partnership between ESTEVE and the research team of Dr. Fàtima Bosch at the Center for Biotechnology and Gene Therapy of the Universitat Autònoma de Barcelona (UAB).

In this partnership, ESTEVE leads all activities associated with the management and protection of intellectual property, regulatory activities, the coordination and supervision of GMP manufacturing, the preclinical toxicology studies as well as all clinical development.
The CBATEG research team at the UAB brings to the partnership their scientific know-how and expertise in gene therapy including viral vector design and the development of preclinical disease models.

Press release

More news

13/04/2023 Panattoni acquires 60,000 sqm land plot to build a data center 16/09/2021 Battery technology in the Barcelona Synchrotron Park environment 06/09/2021 Advances in the creation of a state-of-the-art microscopy platform at the Alba Synchrotron 22/07/2021 IBM, the big blue of technology at the Barcelona Synchrotron Park 02/07/2021 SENER, cutting-edge engineering and technology in the Barcelona Synchrotron Park 11/06/2021 Parc de l'Alba: first injection of landfill gas into the distribution network
1 2 3 4 5 6